Viability measurements of target cancer cells showed that BP-αCD3-αEGFR-ARC Exos can selectively induce cytotoxicity against EGFR-expressing BT-20 and MDA-MB-231 cells with EC50 in a range of 37–174 ng mL−1, but spare MDA-MB-453 cells lacking EGFR expression (Fig. 6B–D). This evidence concerns the gene EGFR and cancer.